25 XP   0   0   10

Hansa Biopharma AB
Buy, Hold or Sell?

Let's analyse Hansa Biopharma AB together

PenkeI guess you are interested in Hansa Biopharma AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hansa Biopharma AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hansa Biopharma AB

I send you an email if I find something interesting about Hansa Biopharma AB.

Quick analysis of Hansa Biopharma AB (30 sec.)










What can you expect buying and holding a share of Hansa Biopharma AB? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€-3.19
Expected worth in 1 year
€-61.72
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
€-58.54
Return On Investment
-2,439.0%

For what price can you sell your share?

Current Price per Share
€2.40
Expected price per share
€1.932 - €3.352
How sure are you?
50%

1. Valuation of Hansa Biopharma AB (5 min.)




Live pricePrice per Share (EOD)

€2.40

Intrinsic Value Per Share

€-173.54 - €-158.35

Total Value Per Share

€-176.73 - €-161.54

2. Growth of Hansa Biopharma AB (5 min.)




Is Hansa Biopharma AB growing?

Current yearPrevious yearGrowGrow %
How rich?-$179.1m$643.3m-$822.4m-459.1%

How much money is Hansa Biopharma AB making?

Current yearPrevious yearGrowGrow %
Making money-$75m-$55.1m-$19.9m-26.5%
Net Profit Margin-620.3%-395.5%--

How much money comes from the company's main activities?

3. Financial Health of Hansa Biopharma AB (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#975 / 1007

Most Revenue
#382 / 1007

Most Profit
#695 / 1007

Most Efficient
#758 / 1007

What can you expect buying and holding a share of Hansa Biopharma AB? (5 min.)

Welcome investor! Hansa Biopharma AB's management wants to use your money to grow the business. In return you get a share of Hansa Biopharma AB.

What can you expect buying and holding a share of Hansa Biopharma AB?

First you should know what it really means to hold a share of Hansa Biopharma AB. And how you can make/lose money.

Speculation

The Price per Share of Hansa Biopharma AB is €2.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hansa Biopharma AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hansa Biopharma AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €-3.19. Based on the TTM, the Book Value Change Per Share is €-14.63 per quarter. Based on the YOY, the Book Value Change Per Share is €-2.94 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hansa Biopharma AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-1.43-59.4%-1.43-59.4%-1.04-43.5%-0.95-39.6%-0.71-29.5%
Usd Book Value Change Per Share-15.61-650.6%-15.61-650.6%-3.13-130.5%-4.16-173.5%-0.43-17.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-15.61-650.6%-15.61-650.6%-3.13-130.5%-4.16-173.5%-0.43-17.7%
Usd Price Per Share2.62-2.62-4.68-9.82-12.87-
Price to Earnings Ratio-1.84--1.84--4.48--12.67--26.89-
Price-to-Total Gains Ratio-0.17--0.17--1.50--0.41-1.09-
Price to Book Ratio-0.77--0.77-0.38-0.38-0.69-
Price-to-Total Gains Ratio-0.17--0.17--1.50--0.41-1.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.5608
Number of shares390
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-15.61-4.16
Usd Total Gains Per Share-15.61-4.16
Gains per Quarter (390 shares)-6,089.56-1,623.94
Gains per Year (390 shares)-24,358.23-6,495.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-24358-243680-6496-6506
20-48716-487260-12991-13002
30-73075-730840-19487-19498
40-97433-974420-25983-25994
50-121791-1218000-32479-32490
60-146149-1461580-38974-38986
70-170508-1705160-45470-45482
80-194866-1948740-51966-51978
90-219224-2192320-58462-58474
100-243582-2435900-64957-64970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.08.00.00.0%0.08.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%4.04.00.050.0%4.04.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.08.00.0%0.00.08.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%4.04.00.050.0%4.04.00.050.0%

Fundamentals of Hansa Biopharma AB

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Fundamental data was last updated by Penke on 2024-04-18 03:24:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Hansa Biopharma AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hansa Biopharma AB earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • A Net Profit Margin of -620.3% means that €-6.20 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hansa Biopharma AB:

  • The MRQ is -620.3%. The company is making a huge loss. -2
  • The TTM is -620.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-620.3%TTM-620.3%0.0%
TTM-620.3%YOY-395.5%-224.8%
TTM-620.3%5Y-4,047.5%+3,427.2%
5Y-4,047.5%10Y-4,632.9%+585.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-620.3%-207.2%-413.1%
TTM-620.3%-218.5%-401.8%
YOY-395.5%-282.4%-113.1%
5Y-4,047.5%-432.2%-3,615.3%
10Y-4,632.9%-593.8%-4,039.1%
1.1.2. Return on Assets

Shows how efficient Hansa Biopharma AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • -6.9% Return on Assets means that Hansa Biopharma AB generated €-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hansa Biopharma AB:

  • The MRQ is -6.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.9%TTM-6.9%0.0%
TTM-6.9%YOY-3.1%-3.8%
TTM-6.9%5Y-4.3%-2.6%
5Y-4.3%10Y-3.6%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.9%-13.2%+6.3%
TTM-6.9%-12.6%+5.7%
YOY-3.1%-11.5%+8.4%
5Y-4.3%-13.7%+9.4%
10Y-3.6%-15.5%+11.9%
1.1.3. Return on Equity

Shows how efficient Hansa Biopharma AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • 0.0% Return on Equity means Hansa Biopharma AB generated €0.00 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hansa Biopharma AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-8.6%+8.6%
TTM-5Y-4.6%+4.6%
5Y-4.6%10Y-3.9%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.7%+16.7%
TTM--15.8%+15.8%
YOY-8.6%-14.4%+5.8%
5Y-4.6%-19.0%+14.4%
10Y-3.9%-19.9%+16.0%

1.2. Operating Efficiency of Hansa Biopharma AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hansa Biopharma AB is operating .

  • Measures how much profit Hansa Biopharma AB makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hansa Biopharma AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-379.9%+379.9%
TTM-5Y-3,914.7%+3,914.7%
5Y-3,914.7%10Y-4,507.8%+593.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.5%+286.5%
TTM--229.1%+229.1%
YOY-379.9%-288.4%-91.5%
5Y-3,914.7%-480.7%-3,434.0%
10Y-4,507.8%-624.7%-3,883.1%
1.2.2. Operating Ratio

Measures how efficient Hansa Biopharma AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 7.37 means that the operating costs are €7.37 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Hansa Biopharma AB:

  • The MRQ is 7.371. The company is inefficient in keeping operating costs low. -1
  • The TTM is 7.371. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.371TTM7.3710.000
TTM7.371YOY4.977+2.394
TTM7.3715Y41.632-34.261
5Y41.63210Y47.230-5.598
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3713.231+4.140
TTM7.3713.307+4.064
YOY4.9773.774+1.203
5Y41.6325.667+35.965
10Y47.2307.558+39.672

1.3. Liquidity of Hansa Biopharma AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hansa Biopharma AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.66 means the company has €2.66 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Hansa Biopharma AB:

  • The MRQ is 2.664. The company is able to pay all its short-term debts. +1
  • The TTM is 2.664. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.664TTM2.6640.000
TTM2.664YOY6.131-3.467
TTM2.6645Y6.603-3.939
5Y6.60310Y8.662-2.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6643.890-1.226
TTM2.6644.182-1.518
YOY6.1315.343+0.788
5Y6.6036.135+0.468
10Y8.6626.453+2.209
1.3.2. Quick Ratio

Measures if Hansa Biopharma AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • A Quick Ratio of 0.24 means the company can pay off €0.24 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hansa Biopharma AB:

  • The MRQ is 0.238. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.238. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.238TTM0.2380.000
TTM0.238YOY0.032+0.206
TTM0.2385Y1.658-1.421
5Y1.65810Y2.104-0.446
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2383.528-3.290
TTM0.2384.059-3.821
YOY0.0325.390-5.358
5Y1.6586.138-4.480
10Y2.1046.488-4.384

1.4. Solvency of Hansa Biopharma AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hansa Biopharma AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hansa Biopharma AB to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.16 means that Hansa Biopharma AB assets are financed with 116.5% credit (debt) and the remaining percentage (100% - 116.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hansa Biopharma AB:

  • The MRQ is 1.165. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.165. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.165TTM1.1650.000
TTM1.165YOY0.643+0.522
TTM1.1655Y0.469+0.696
5Y0.46910Y0.325+0.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1650.339+0.826
TTM1.1650.337+0.828
YOY0.6430.273+0.370
5Y0.4690.368+0.101
10Y0.3250.391-0.066
1.4.2. Debt to Equity Ratio

Measures if Hansa Biopharma AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hansa Biopharma AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1.799-1.799
TTM-5Y0.494-0.494
5Y0.49410Y0.343+0.151
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM-0.403-0.403
YOY1.7990.342+1.457
5Y0.4940.432+0.062
10Y0.3430.461-0.118

2. Market Valuation of Hansa Biopharma AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Hansa Biopharma AB generates.

  • Above 15 is considered overpriced but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • A PE ratio of -1.84 means the investor is paying €-1.84 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hansa Biopharma AB:

  • The EOD is -1.797. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.835. Based on the earnings, the company is expensive. -2
  • The TTM is -1.835. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.797MRQ-1.835+0.039
MRQ-1.835TTM-1.8350.000
TTM-1.835YOY-4.484+2.648
TTM-1.8355Y-12.668+10.833
5Y-12.66810Y-26.894+14.226
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.797-2.249+0.452
MRQ-1.835-2.553+0.718
TTM-1.835-2.669+0.834
YOY-4.484-4.107-0.377
5Y-12.668-6.247-6.421
10Y-26.894-6.499-20.395
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hansa Biopharma AB:

  • The EOD is -0.181. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.185. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.185. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.181MRQ-0.185+0.004
MRQ-0.185TTM-0.1850.000
TTM-0.185YOY-0.457+0.272
TTM-0.1855Y-1.392+1.207
5Y-1.39210Y-2.756+1.364
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.181-2.858+2.677
MRQ-0.185-3.288+3.103
TTM-0.185-3.552+3.367
YOY-0.457-5.560+5.103
5Y-1.392-8.326+6.934
10Y-2.756-8.881+6.125
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hansa Biopharma AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.77 means the investor is paying €-0.77 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Hansa Biopharma AB:

  • The EOD is -0.753. Based on the equity, the company is expensive. -2
  • The MRQ is -0.769. Based on the equity, the company is expensive. -2
  • The TTM is -0.769. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.753MRQ-0.769+0.016
MRQ-0.769TTM-0.7690.000
TTM-0.769YOY0.384-1.153
TTM-0.7695Y0.376-1.146
5Y0.37610Y0.691-0.314
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.7531.929-2.682
MRQ-0.7692.090-2.859
TTM-0.7692.091-2.860
YOY0.3842.881-2.497
5Y0.3763.545-3.169
10Y0.6913.936-3.245
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hansa Biopharma AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---14.634-14.6340%-2.936-80%-3.902-73%-0.398-97%
Book Value Per Share---3.187-3.1870%11.447-128%11.382-128%11.324-128%
Current Ratio--2.6642.6640%6.131-57%6.603-60%8.662-69%
Debt To Asset Ratio--1.1651.1650%0.643+81%0.469+148%0.325+259%
Debt To Equity Ratio----0%1.799-100%0.494-100%0.343-100%
Dividend Per Share----0%-0%-0%-0%
Eps---1.336-1.3360%-0.979-27%-0.890-33%-0.664-50%
Free Cash Flow Per Share---13.227-13.2270%-9.608-27%-8.791-34%-7.254-45%
Free Cash Flow To Equity Per Share---13.227-13.2270%11.639-214%-0.546-96%1.253-1156%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---158.350--------
Intrinsic Value_10Y_min---173.543--------
Intrinsic Value_1Y_max---10.340--------
Intrinsic Value_1Y_min---12.492--------
Intrinsic Value_3Y_max---35.279--------
Intrinsic Value_3Y_min---41.999--------
Intrinsic Value_5Y_max---65.299--------
Intrinsic Value_5Y_min---76.173--------
Market Cap126412320.000-2%129151253.600129151253.6000%231229202.000-44%484780712.840-73%635188988.125-80%
Net Profit Margin---6.203-6.2030%-3.955-36%-40.475+553%-46.329+647%
Operating Margin----0%-3.7990%-39.1470%-45.0780%
Operating Ratio--7.3717.3710%4.977+48%41.632-82%47.230-84%
Pb Ratio-0.753+2%-0.769-0.7690%0.384-301%0.376-304%0.691-211%
Pe Ratio-1.797+2%-1.835-1.8350%-4.484+144%-12.668+590%-26.894+1365%
Price Per Share2.400-2%2.4522.4520%4.390-44%9.204-73%12.059-80%
Price To Free Cash Flow Ratio-0.181+2%-0.185-0.1850%-0.457+146%-1.392+651%-2.756+1387%
Price To Total Gains Ratio-0.164+2%-0.168-0.1680%-1.495+792%-0.413+146%1.085-115%
Quick Ratio--0.2380.2380%0.032+644%1.658-86%2.104-89%
Return On Assets---0.069-0.0690%-0.031-56%-0.043-37%-0.036-47%
Return On Equity----0%-0.0860%-0.0460%-0.0390%
Total Gains Per Share---14.634-14.6340%-2.936-80%-3.902-73%-0.398-97%
Usd Book Value---179123692.000-179123692.0000%643307104.000-128%639676743.200-128%636435890.750-128%
Usd Book Value Change Per Share---15.614-15.6140%-3.133-80%-4.164-73%-0.425-97%
Usd Book Value Per Share---3.401-3.4010%12.214-128%12.145-128%12.083-128%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.425-1.4250%-1.045-27%-0.950-33%-0.708-50%
Usd Free Cash Flow---743363962.000-743363962.0000%-539970288.000-27%-494039779.200-34%-356732110.625-52%
Usd Free Cash Flow Per Share---14.113-14.1130%-10.252-27%-9.380-34%-7.740-45%
Usd Free Cash Flow To Equity Per Share---14.113-14.1130%12.419-214%-0.583-96%1.337-1156%
Usd Market Cap134881945.440-2%137804387.591137804387.5910%246721558.534-44%517261020.600-73%677746650.329-80%
Usd Price Per Share2.561-2%2.6162.6160%4.684-44%9.820-73%12.867-80%
Usd Profit---75077867.304-75077867.3040%-55165966.139-27%-50044653.973-33%-37323203.938-50%
Usd Revenue--12104424.01112104424.0110%13948693.605-13%5993068.281+102%3851495.856+214%
Usd Total Gains Per Share---15.614-15.6140%-3.133-80%-4.164-73%-0.425-97%
 EOD+2 -6MRQTTM+0 -0YOY+5 -265Y+7 -2410Y+6 -25

3.2. Fundamental Score

Let's check the fundamental score of Hansa Biopharma AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.797
Price to Book Ratio (EOD)Between0-1-0.753
Net Profit Margin (MRQ)Greater than0-6.203
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.238
Current Ratio (MRQ)Greater than12.664
Debt to Asset Ratio (MRQ)Less than11.165
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.069
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Hansa Biopharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.701
Ma 20Greater thanMa 502.465
Ma 50Greater thanMa 1002.576
Ma 100Greater thanMa 2002.599
OpenGreater thanClose2.372
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Total Stockholder Equity 562,815679,3091,242,124-484,551757,573-154,661602,912-770,788-167,876



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets1,018,041
Total Liabilities1,185,917
Total Stockholder Equity-167,876
 As reported
Total Liabilities 1,185,917
Total Stockholder Equity+ -167,876
Total Assets = 1,018,041

Assets

Total Assets1,018,041
Total Current Assets855,151
Long-term Assets162,890
Total Current Assets
Cash And Cash Equivalents 732,060
Net Receivables 76,266
Inventory 1,513
Total Current Assets  (as reported)855,151
Total Current Assets  (calculated)809,839
+/- 45,312
Long-term Assets
Property Plant Equipment 27,073
Intangible Assets 135,817
Long-term Assets  (as reported)162,890
Long-term Assets  (calculated)162,890
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities320,988
Long-term Liabilities864,929
Total Stockholder Equity-167,876
Total Current Liabilities
Accounts payable 86,966
Other Current Liabilities 49,266
Total Current Liabilities  (as reported)320,988
Total Current Liabilities  (calculated)136,232
+/- 184,756
Long-term Liabilities
Long term Debt 844,903
Capital Lease Obligations Min Short Term Debt21,865
Long-term Liabilities Other 843
Long-term Liabilities  (as reported)864,929
Long-term Liabilities  (calculated)867,611
+/- 2,682
Total Stockholder Equity
Total Stockholder Equity (as reported)-167,876
Total Stockholder Equity (calculated)0
+/- 167,876
Other
Capital Stock55,034
Common Stock Shares Outstanding 52,672
Net Debt 112,843
Net Invested Capital 677,027
Net Working Capital 534,163
Property Plant and Equipment Gross 36,394



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
310,672
680,415
944,821
664,236
1,434,496
1,012,808
1,687,406
1,018,041
1,018,0411,687,4061,012,8081,434,496664,236944,821680,415310,672
   > Total Current Assets 
256,982
624,182
866,220
615,744
1,393,387
942,342
1,604,704
855,151
855,1511,604,704942,3421,393,387615,744866,220624,182256,982
       Cash And Cash Equivalents 
213,588
581,078
439,441
181,697
1,139,362
651,342
1,496,179
732,060
732,0601,496,179651,3421,139,362181,697439,441581,078213,588
       Short-term Investments 
39,990
34,983
418,746
419,397
238,144
237,619
0
0
00237,619238,144419,397418,74634,98339,990
       Net Receivables 
2,839
7,901
7,410
5,256
110
9,712
8,360
76,266
76,2668,3609,7121105,2567,4107,9012,839
       Other Current Assets 
0
0
149
6,735
6,428
26,561
1
0
0126,5616,4286,73514900
   > Long-term Assets 
53,690
56,233
78,601
48,493
41,109
70,466
82,702
162,890
162,89082,70270,46641,10948,49378,60156,23353,690
       Property Plant Equipment 
2,570
3,976
5,876
15,144
9,700
45,784
35,836
27,073
27,07335,83645,7849,70015,1445,8763,9762,570
       Intangible Assets 
36,554
33,749
33,197
33,348
31,410
28,761
46,866
135,817
135,81746,86628,76131,41033,34833,19733,74936,554
       Long-term Assets Other 
0
0
0
1
-1
-4,079
0
0
00-4,079-11000
> Total Liabilities 
26,979
49,754
84,945
101,421
192,372
255,235
1,084,494
1,185,917
1,185,9171,084,494255,235192,372101,42184,94549,75426,979
   > Total Current Liabilities 
25,732
43,598
72,331
94,540
114,203
171,219
261,716
320,988
320,988261,716171,219114,20394,54072,33143,59825,732
       Accounts payable 
6,482
3,771
40,426
50,573
26,669
53,360
80,754
86,966
86,96680,75453,36026,66950,57340,4263,7716,482
       Other Current Liabilities 
10,428
24,714
14,835
7,647
30,763
32,942
67,443
49,266
49,26667,44332,94230,7637,64714,83524,71410,428
   > Long-term Liabilities 
1,247
6,156
12,614
6,881
78,169
84,016
819,781
864,929
864,929819,78184,01678,1696,88112,6146,1561,247
       Capital Lease Obligations Min Short Term Debt
48
0
577
9,459
5,045
35,379
28,491
21,865
21,86528,49135,3795,0459,459577048
       Other Liabilities 
1,243
6,156
12,138
2,054
77,539
55,525
35,854
0
035,85455,52577,5392,05412,1386,1561,243
> Total Stockholder Equity
283,693
630,661
859,876
562,815
1,242,124
757,573
602,912
-167,876
-167,876602,912757,5731,242,124562,815859,876630,661283,693
   Common Stock
35,055
38,208
40,682
41,448
45,895
46,335
605,909
0
0605,90946,33545,89541,44840,68238,20835,055
   Retained Earnings Total Equity00000000
   Accumulated Other Comprehensive Income 00000000
   Capital Surplus 00000000
   Treasury Stock00000000
   Other Stockholders Equity 
6,288
9,801
31,216
81,162
-137
128
0
0
00128-13781,16231,2169,8016,288



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue134,094
Cost of Revenue-63,143
Gross Profit70,95170,951
 
Operating Income (+$)
Gross Profit70,951
Operating Expense-925,253
Operating Income-791,159-854,302
 
Operating Expense (+$)
Research Development411,332
Selling General Administrative450,492
Selling And Marketing Expenses-
Operating Expense925,253861,824
 
Net Interest Income (+$)
Interest Income27,992
Interest Expense-105,520
Other Finance Cost-0
Net Interest Income-77,528
 
Pretax Income (+$)
Operating Income-791,159
Net Interest Income-77,528
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-830,812-791,159
EBIT - interestExpense = -105,520
-831,720
-726,200
Interest Expense105,520
Earnings Before Interest and Taxes (EBIT)--725,292
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-830,812
Tax Provision-908
Net Income From Continuing Ops-831,720-831,720
Net Income-831,720
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-77,528
 

Technical Analysis of Hansa Biopharma AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hansa Biopharma AB. The general trend of Hansa Biopharma AB is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hansa Biopharma AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hansa Biopharma AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.45 < 2.758 < 3.352.

The bearish price targets are: 2.144 > 1.978 > 1.932.

Tweet this
Hansa Biopharma AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hansa Biopharma AB. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hansa Biopharma AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hansa Biopharma AB. The current macd is -0.07120497.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hansa Biopharma AB price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hansa Biopharma AB. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hansa Biopharma AB price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Hansa Biopharma AB Daily Moving Average Convergence/Divergence (MACD) ChartHansa Biopharma AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hansa Biopharma AB. The current adx is 14.08.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Hansa Biopharma AB shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Hansa Biopharma AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hansa Biopharma AB. The current sar is 2.56912587.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hansa Biopharma AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hansa Biopharma AB. The current rsi is 46.70. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Hansa Biopharma AB Daily Relative Strength Index (RSI) ChartHansa Biopharma AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hansa Biopharma AB. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hansa Biopharma AB price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Hansa Biopharma AB Daily Stochastic Oscillator ChartHansa Biopharma AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hansa Biopharma AB. The current cci is -42.54477095.

Hansa Biopharma AB Daily Commodity Channel Index (CCI) ChartHansa Biopharma AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hansa Biopharma AB. The current cmo is -2.60922031.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hansa Biopharma AB Daily Chande Momentum Oscillator (CMO) ChartHansa Biopharma AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hansa Biopharma AB. The current willr is -60.28037383.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hansa Biopharma AB is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hansa Biopharma AB Daily Williams %R ChartHansa Biopharma AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hansa Biopharma AB.

Hansa Biopharma AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hansa Biopharma AB. The current atr is 0.09126507.

Hansa Biopharma AB Daily Average True Range (ATR) ChartHansa Biopharma AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hansa Biopharma AB. The current obv is 6,548.

Hansa Biopharma AB Daily On-Balance Volume (OBV) ChartHansa Biopharma AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hansa Biopharma AB. The current mfi is 38.00.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Hansa Biopharma AB Daily Money Flow Index (MFI) ChartHansa Biopharma AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hansa Biopharma AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-27 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-15 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-16 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-05 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-20 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-01 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-05 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-08 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-15 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Hansa Biopharma AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hansa Biopharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.701
Ma 20Greater thanMa 502.465
Ma 50Greater thanMa 1002.576
Ma 100Greater thanMa 2002.599
OpenGreater thanClose2.372
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hansa Biopharma AB with someone you think should read this too:
  • Are you bullish or bearish on Hansa Biopharma AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hansa Biopharma AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hansa Biopharma AB

I send you an email if I find something interesting about Hansa Biopharma AB.


Comments

How you think about this?

Leave a comment

Stay informed about Hansa Biopharma AB.

Receive notifications about Hansa Biopharma AB in your mailbox!